The last participant has received treatment in a Food and Drug Administration Investigational Device Exemption (FDA IDE) study investigating the efficacy of Eye90 microspheres® in managing unresectable Hepatocellular Carcinoma (HCC). This significant development occurred in Halifax, NS on February 24, 2026. ABK Biomedical, Inc., a pioneering medical device business committed to advancing the treatment landscape, led the study.